Discrepancies in the assessment of axial spondyloarthritis between patients and rheumatologists: what does this mean?

• by Daniel Wendling, Olivier Fakih, Frank Verhoeven, Clément Prati

• May 23, 2026

RA Outcomes Improved in KURAMA Cohort

Ten-year observational data showed lower disease activity and functional disability coinciding with broader use of biologic and targeted synthetic therapies.

• by Andrea Surnit

• May 22, 2026

• 4 min

JAK Monotherapy Shows Efficacy in RA Review

A systematic review found Janus kinase inhibitor monotherapy improved outcomes vs methotrexate or placebo, but direct comparisons with combination therapy were limited.

• by Andrea Surnit

• May 22, 2026

• 4 min

FDA Clears Golimumab Biosimilars

New biosimilars enter the market with pharmacy-level substitution eligibility for rheumatology and gastroenterology indications.

• by Kathryn Wighton

• May 18, 2026

• 2 min